New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
08:44 EDTTINYHarris & Harris signs several agreements with Patia Biopharma
Harris & Harris notes the announcement by its portfolio company, Metabolon that it has signed several exclusive multi-year, royalty-based research collaboration and licensing agreements with Patia Biopharma. The research collaboration provides Metabolon's Quantose IR technology for use in several diabetes prevention studies in Mexico. The license agreement provides exclusive access in Mexico to Metabolon's prediabetes test technology for assessing insulin resistance in the general population of Mexico through Patia and Clinica Ruiz's network of laboratories. Under the terms of the agreements, Patia and its affiliates will use Metabolon's Quantose IR technology in unprecedented large-scale studies in Mexico to test for prediabetes in up to 3M overweight or obese adults and secondary school students who are obese and/or have a family history of diabetes. The goal of these studies is to detect prediabetes early and prescribe treatment to prevent progression to Type 2 diabetes. Testing will be carried out over four years, beginning with pilot studies in FY14.
News For TINY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for TINY

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use